KODKodiak Sciences Inc.
Price
+207%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 11% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for KOD today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Mixed
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
Kodiak has developed three late-stage clinical programs based on its internal discovery and development engine. The lead investigational medicine, tarcocimab tedromer (“Zenkuda” or “KSI-301” or “tarcocimab”), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Zenkuda has a mean ocular half-life in humans of 20 days, approximately three times longer than approved anti-vascular endothelial growth factor ("VEGF") therapies, and is designed to maintain effective drug levels in ocular tissues for longer.
In the company’s own words · 10-K filed Mar 31, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 28, 2026On September 28, 2026, Kodiak Sciences Inc. (the “Company”) issued a press release announcing that the primary endpoints were met for both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in the Company’s Phase 3 DAYBREAK study in patients with wet age-related macular degeneration.Other event · Form 8-K
- Aug 13, 2026Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results.Earnings release · press release
- May 7, 2026Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.